MK-2206

MK-2206
Names
	IUPAC name 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one
Identifiers
3D model (JSmol)	Interactive image;
ChemSpider	24658140;
ECHA InfoCard	100.207.435
PubChem CID	24964624;
CompTox Dashboard (EPA)	DTXSID3048948 ;
	InChI InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31) Key: ULDXWLCXEDXJGE-UHFFFAOYSA-N; InChI=1/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31) Key: ULDXWLCXEDXJGE-UHFFFAOYAX;
	SMILES C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N;
Properties
Chemical formula	C25H21N5O
Molar mass	407.477 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C₂₅H₂₁N₅O.[1] It acts as an allosteric AKT inhibitor.[2]

It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3.[1]

It is intended to be used with other cancer therapies that advanced tumours may become resistant to.[3]

Clinical trials

2011: A phase 1 clinical trial of MK-2206 alone has reported it was well tolerated.[4]
2014: A phase 1 clinical trial of MK-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects.[3]
2016: MK-2206 is one of the treatments in the I-SPY2 Adaptive clinical trial for breast cancer that had been selected for later stage trials.[5]
As of August 2017 31 phase II clinical trials are registered, many completed.[6] e.g. in colorectal cancer, breast cancer, and many others.

References

MK-2206 dihydrochloride (CAS 1032350-13-2) inc structure diagram
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Hirai et al. 2010
A trial of MK-2206 with chemotherapy or erlotinib for advanced cancer
Yap, TA; Yan, L; Patnaik, A; Fearen, I; Olmos, D; Papadopoulos, K; Baird, RD; Delgado, L; Taylor, A; Lupinacci, L; Riisnaes, R; Pope, LL; Heaton, SP; Thomas, G; Garrett, MD; Sullivan, DM; de Bono, JS; Tolcher, AW (2011). "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors". J Clin Oncol. 29: 4688–95. doi:10.1200/JCO.2011.35.5263. PMID 22025163.
Novel Agents are Targeting Drivers of TNBC - Several drug candidates in I-SPY2 have 'graduated' to later-phase studies. June 2016
MK-2206 phase=2 trials

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[SCB-1] MK-2206 dihydrochloride (CAS 1032350-13-2) inc structure diagram

[Hirai2010-2] MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Hirai et al. 2010

[CRUK-3] A trial of MK-2206 with chemotherapy or erlotinib for advanced cancer

[Yap2010-4] Yap, TA; Yan, L; Patnaik, A; Fearen, I; Olmos, D; Papadopoulos, K; Baird, RD; Delgado, L; Taylor, A; Lupinacci, L; Riisnaes, R; Pope, LL; Heaton, SP; Thomas, G; Garrett, MD; Sullivan, DM; de Bono, JS; Tolcher, AW (2011). "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors". J Clin Oncol. 29: 4688–95. doi:10.1200/JCO.2011.35.5263. PMID 22025163.

[5] Novel Agents are Targeting Drivers of TNBC - Several drug candidates in I-SPY2 have 'graduated' to later-phase studies. June 2016

[6] MK-2206 phase=2 trials